VYNE Therapeutics (NASDAQ:VYNE – Get Rating)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Friday, TipRanks reports. They currently have a $7.00 price objective on the stock. Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of VYNE Therapeutics in a report on Friday, March 18th. […]
VYNE Therapeutics (NASDAQ:VYNE – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “VYNE Therapeutics Inc. focuses on developing and commercializing therapeutics for dermatology. The company’s product pipeline consist FMX103 and FCD105 which are […]
VYNE Therapeutics (NASDAQ:VYNE – Get Rating) and Seelos Therapeutics (NASDAQ:SEEL – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a summary of recent ratings […]
Brokerages expect VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Rating) to announce $550,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for VYNE Therapeutics’ earnings, with estimates ranging from $300,000.00 to $800,000.00. VYNE Therapeutics posted sales of $4.12 million during the same quarter last year, which would indicate a […]